Time-to-progression ratio as a potential study endpoint in early-phase oncology trials: pooled analysis of phase II trials from the Australian MoST program. - Siu DHW; Lin FPY; Thomas DM; Thavaneswaran S; Espinoza D; Chinchen S; Ballinger ML; Simes RJ; Lee CK (Future oncology (London, England), 2026)